Azacitidine + Ruxolitinib combination

Current understanding

To be populated as evidence accumulates.

2026-06-16 — Final analysis of phase 2 clinical trial of ruxolitinib and azacitidine combination therapy in patients with myelodysplastic syndrome/myeloproliferative neoplasms.: Final Phase 2 analysis (trial-early) in MDS/MPN overlap: azacitidine + ruxolitinib achieved 58% objective response rate with median OS of 26.7 months and manageable safety, with particularly encouraging survival among patients proceeding to subsequent allogeneic transplant — extends the combination’s activity signal from MF into the MDS/MPN overlap population. (novelty: 3)
2026-08-27 — Final results of a phase II study of the combination of azacitidine and ruxolitinib in patients with myelofibrosis.: Final phase II results (trial-early): azacitidine + ruxolitinib in myelofibrosis achieved high objective response rates by IWG-MRT criteria, supporting the combination as a disease-modifying strategy beyond ruxolitinib monotherapy. (novelty: 3)